These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38424474)

  • 1. The
    Sherkow JS; Cook-Deegan R; Greely HT
    Annu Rev Genomics Hum Genet; 2024 Aug; 25(1):397-419. PubMed ID: 38424474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do recent US Supreme Court rulings on patenting of genes and genetic diagnostics affect the practice of genetic screening and diagnosis in prenatal and reproductive care?
    Chandrasekharan S; McGuire AL; Van den Veyver IB
    Prenat Diagn; 2014 Oct; 34(10):921-6. PubMed ID: 24989832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene patents and personalized cancer care: impact of the Myriad case on clinical oncology.
    Offit K; Bradbury A; Storm C; Merz JF; Noonan KE; Spence R
    J Clin Oncol; 2013 Jul; 31(21):2743-8. PubMed ID: 23766521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Take off your genes and let the doctor have a look: why the Mayo and Myriad decisions have invalidated method claims for genetic diagnostic testing.
    Bergin C
    Am Univ Law Rev; 2013; 63(1):173-217. PubMed ID: 25335200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The History of Patenting Genetic Material.
    Sherkow JS; Greely HT
    Annu Rev Genet; 2015; 49():161-82. PubMed ID: 26442843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of Myriad and Mayo: will advancements in the biological sciences be spurred or disincentivized? (Or was biotech patenting not complicated enough?).
    Gordon J
    Cold Spring Harb Perspect Med; 2014 Dec; 5(5):a020917. PubMed ID: 25502748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene patents, patenting life and the impact of court rulings on US stem cell patents and research.
    Matthews KR; Cuchiara ML
    Regen Med; 2014 Mar; 9(2):191-200. PubMed ID: 24750060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Supreme Court to Myriad Genetics: Synthetic DNA is Patentable but Isolated Genes Are Not.
    Weinmeyer R; Klusty T
    AMA J Ethics; 2015 Sep; 17(9):849-53. PubMed ID: 26390207
    [No Abstract]   [Full Text] [Related]  

  • 9. The Federal Circuit's decision in Myriad: isolated DNA molecules are patentable subject matter.
    Ogden SR
    Am Univ Law Rev; 2011; 61(2):443-56. PubMed ID: 25335196
    [No Abstract]   [Full Text] [Related]  

  • 10. Baseball bats and chocolate chip cookies: the judicial treatment of DNA in the myriad genetics litigation.
    Binnie I; Park-Thompson V
    Cold Spring Harb Perspect Med; 2014 Dec; 5(6):. PubMed ID: 25524722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patentable subject matter, TRIPS and the European Biotechnology Directive: Australia and patenting human genes.
    Palombi L
    Univ N S W Law J; 2003; 26(3):782-92. PubMed ID: 16617532
    [No Abstract]   [Full Text] [Related]  

  • 12. Mayo, Myriad, America Invents Act and BPCIA: how has the United States biopharmaceutical market been affected?
    Finston SK; Davey NS; Davé E; Ravichandran V; Davey SR; Davé RS
    Pharm Pat Anal; 2016 May; 5(3):159-67. PubMed ID: 27087460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Invalidating human gene patenting: the U.S. Supreme Court rules in Association for Molecular Pathology v. Myriad Genetics.
    Kalyvas J; Little AS
    World Neurosurg; 2013 Dec; 80(6):680-1. PubMed ID: 24134909
    [No Abstract]   [Full Text] [Related]  

  • 14. Patent protection of diagnostic technology: will recent US Supreme Court decisions change patent strategy?
    Komatani TS
    Pharm Pat Anal; 2015; 4(5):357-62. PubMed ID: 26451906
    [No Abstract]   [Full Text] [Related]  

  • 15. Patenting genes: what does Association for Molecular Pathology v. Myriad Genetics mean for genetic testing and research?
    Cartwright-Smith L
    Public Health Rep; 2014 May; 129(3):289-92. PubMed ID: 24790252
    [No Abstract]   [Full Text] [Related]  

  • 16. MYRIAD AFTER
    Conley JM; Cook-Deegan R; Lázaro-Muñoz G
    N C J Law Technol; 2014 Jun; 15(4):597-637. PubMed ID: 25544836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myriad's impact on gene patents.
    Aboy M; Liddell K; Liddicoat J; Crespo C
    Nat Biotechnol; 2016 Nov; 34(11):1119-1123. PubMed ID: 27824831
    [No Abstract]   [Full Text] [Related]  

  • 18. Harvard v. Canada: the myc mouse that still squeaks in the maze of biopatent law.
    Deftos LJ
    Acad Med; 2001 Jul; 76(7):684-92. PubMed ID: 11448821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patent law--patent on life form--man-made modification of microorganism is patentable subject matter under 35 U.S.C. 101--Diamond v. Chakrabarty, 100 S.Ct. 2204 (1980).
    Vidas S
    Hamline Law Rev; 1981 Jan; 4(2):341-50. PubMed ID: 11650724
    [No Abstract]   [Full Text] [Related]  

  • 20. Patent portfolios after myriad, how to fit in those new genes?
    Aceto JF
    ACS Med Chem Lett; 2013 Aug; 4(8):681-3. PubMed ID: 24900729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.